Abstract
Human-induced pluripotent stem cell-derived hepatocyte-like cells (iHeps) constitute a powerful tool for modeling hepatotropic pathogen infections in cell culture. Meanwhile, CRISPR-Cas9 technology enables precise editing of stem cell genomes to generate patient-specific disease models and thus development of personalized experimental systems. Here we present a detailed stepwise protocol for the differentiation of stem cells to hepatocyte-like cells for HCV studies in cell culture. We also outline the use of an inducible iCRISPR platform for the rapid and efficient modification of host factors of interest to better understand their function during HCV infection.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Goossens N, Hoshida Y (2015) Personalized management of hepatocellular carcinoma based on molecular information: future prospects. Clin Liver Dis 5:132–135
Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P et al (2016) Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 65:727–733
Reig M, Marino Z, Perello C, Inarrairaegui M, Ribeiro A, Lens S et al (2016) Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 65:719–726
Asselah T, Bieche I, Sabbagh A, Bedossa P, Moreau R, Valla D et al (2009) Gene expression and hepatitis C virus infection. Gut 58:846–858
Heim MH (2013) 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat Rev Immunol 13:535–542
Patin E, Kutalik Z, Guergnon J, Bibert S, Nalpas B, Jouanguy E et al (2012) Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology 143:1244–1252
Wu X, Robotham JM, Lee E, Dalton S, Kneteman NM, Gilbert DM et al (2012) Productive hepatitis C virus infection of stem cell-derived hepatocytes reveals a critical transition to viral permissiveness during differentiation. PLoS Pathog 8:e1002617
Schwartz RE, Trehan K, Andrus L, Sheahan TP, Ploss A, Duncan SA et al (2012) Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proc Natl Acad Sci U S A 109:2544–2548
Shlomai A, Schwartz RE, Ramanan V, Bhatta A, de Jong YP, Bhatia SN et al (2014) Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems. Proc Natl Acad Sci U S A 111:12193–12198
Carpentier A, Tesfaye A, Chu V, Nimgaonkar I, Zhang F, Lee SB et al (2014) Engrafted human stem cell-derived hepatocytes establish an infectious HCV murine model. J Clin Invest 124:4953–4964
Paganelli M, Dallmeier K, Nyabi O, Scheers I, Kabamba B, Neyts J et al (2013) Differentiated umbilical cord matrix stem cells as a new in vitro model to study early events during hepatitis B virus infection. Hepatology 57:59–69
Roelandt P, Obeid S, Paeshuyse J, Vanhove J, Van Lommel A, Nahmias Y et al (2012) Human pluripotent stem cell-derived hepatocytes support complete replication of hepatitis C virus. J Hepatol 57:246–251
Yoshida T, Takayama K, Kondoh M, Sakurai F, Tani H, Sakamoto N et al (2011) Use of human hepatocyte-like cells derived from induced pluripotent stem cells as a model for hepatocytes in hepatitis C virus infection. Biochem Biophys Res Commun 416:119–124
Kaneko S, Kakinuma S, Asahina Y, Kamiya A, Miyoshi M, Tsunoda T et al (2016) Human induced pluripotent stem cell-derived hepatic cell lines as a new model for host interaction with hepatitis B virus. Sci Rep 6:29358
Pan-Genotype Hepatitis E Virus Replication in Stem Cell-Derived Hepatocellular Systems
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K et al (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861–872
Gonzalez F, Zhu Z, Shi ZD, Lelli K, Verma N, Li QV et al (2014) An iCRISPR platform for rapid, multiplexable, and inducible genome editing in human pluripotent stem cells. Cell Stem Cell 15:215–226
Lindenbach BD, Meuleman P, Ploss A, Vanwolleghem T, Syder AJ, McKeating JA et al (2006) Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A 103:3805–3809
Jones CT, Catanese MT, Law LM, Khetani SR, Syder AJ, Ploss A et al (2010) Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Nat Biotechnol 28:167–171
Zhou X, Sun P, Lucendo-Villarin B, Angus AG, Szkolnicka D, Cameron K et al (2014) Modulating innate immunity improves hepatitis C virus infection and replication in stem cell-derived hepatocytes. Stem Cell Reports 3:204–214
Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L et al (2011) EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 17:589–595
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Wu, X., Dao Thi, V.L. (2019). Embryonic or Induced Pluripotent Stem Cell-Derived Hepatocellular Systems for HCV Culture. In: Law, M. (eds) Hepatitis C Virus Protocols . Methods in Molecular Biology, vol 1911. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8976-8_8
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8976-8_8
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8975-1
Online ISBN: 978-1-4939-8976-8
eBook Packages: Springer Protocols